Arius Research licenses anticancer antibody to Genentech

By Elaine Rigoli

Tampa, Fla., March 22 - Arius Research, Inc. announced Wednesday that it has licensed to Genentech, Inc. rights to one of Arius' anticancer antibodies and others in the same family for development in human disease.

Under the agreement, Arius will receive an upfront licensing fee and may receive milestone payments based on progress through clinical development as well as royalties on net sales of any products resulting from the collaboration, according to a company news release.

Genentech will assume the responsibility and costs of development and commercialization, the release said.

No further financial terms were disclosed.

The agreement represents the first anticancer antibody developed from Arius' FunctionFirst platform to be out-licensed.

Arius is a biotechnology company dedicated to personalizing cancer therapy through the discovery and development of anticancer monoclonal antibodies. The company is located in Toronto, Ont.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.